Muñoz A¹*, Martínez MT³, Rojas P² and Carvajal C⁴

¹Department of Ophthalmology, Clinica Las Condes, Chile
²Fundación Oftalmológica Los Andes, Universidad de Los Andes, Chile
³Department of Ophthalmology, Fundación Oftalmológica Los Andes, Universidad de Los Andes, Chile
⁴Department of Radiology, Pontificia Universidad Católica de Chile, Chile

*Corresponding Author: Muñoz A, Department of Ophthalmology, Clinica Las Condes, Chile.

Received: December 27, 2021; Published: February 14, 2022

Abstract

Tacrolimus is an immunosuppressant drug used in solid organ transplantation to reduce rejection rates and to prevent graft versus host disease (GVHD) in haematopoietic stem cell transplantation (HSCT). Tacrolimus is a fungal metabolite produced by Streptomyces tsukubaenis. It works as a calcineurin inhibitor reducing interleukine-2 (IL-2) production and activation of T cells [1]. Along with cyclosporine and other calcineurin inhibitors, tacrolimus is associated with posterior reversible encephalopathy syndrome (PRES) [2], optic neuropathy and only a few cases reported in the literature of maculopathy. About one-third of patients who develop PRES can present visual impairment, most of them fully recover after drug suspension, although there have been partial recovery cases reported [3].

Keywords: Tacrolimus; Maculopathy; Posterior Reversible Encephalopathy Syndrome (PRES)

References

1. Azzi J R., et al. “Calcineurin Inhibitors: 40 Years La- ter, Can’t Live Without”. The Journal of Immunology,12 (2013): 5785-5791.
2. Hinchey J., et al. “A reversible posterior leukoencephalopathy syndrome”. The New England Journal of Medicine 334 (1996): 494-500.
3. Legriel S., et al. “Determinants of recovery from severe posterior reversible encephalopathy syndrome”. PLoS One11 (2013).
4. Young NS., et al. “The epidemiology of acquired aplastic anemia”. Haematologica4 (2008): 489.
5. Bejanyan N., et al. “Choice of conditioning regimens for bone mar- row transplantation in severe aplastic anemia”. Blood Advances20 (2019): 3123‐3131.
6. Fugate JE., et al. “Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings”. Mayo Clinic Proceedings5 (2019): 427-432.
7. Steg RE., et al. “Cortical blindness and seizures in a patient re- ceiving FK506 after bone marrow transplantation”. Bone Marrow Transplantation 23 (1999): 959-962.
8. Kommana SS., et al. “A Case of Tacrolimus-Induced Posterior Reversible Encephalopathy Syndrome Initially Presenting as a Bilateral Optic Neuropathy”. Case Reports in Ophthalmology 1 (2019): 140-144.
9. Taehyuk Koh., et al. “Maculopathy Associated with Tacrolimus (FK 506)”. Korean Journal of Ophthalmology 1 (2011): 69-71.
10. Chen Z., et al. “Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome”. Brain Research Bulletin 131 (2017): 93-99.
11. Rabinstein AA., et al. “Blood pressure fluctuations in posterior reversible encephalopathy syndrome”. Journal of Stroke and Cerebrovascular Diseases 21 (2012): 254-258.
12. Kimsa M., et al. “Transforming growth factor β-related genes in human retinal pigment epithelial cells after tacrolimus treatment”. Pharmacology Report5 (2016): 969-974.

Citation

Citation: Muñoz A., et al. “Maculopathy and Posterior Reversible Encephalopathy Syndrome Presumably Associated with Tacrolimus”.Acta Scientific Medical Sciences 6.3 (2022): 56-59.

Copyright

Copyright: © 2022 Muñoz A., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.